Jump to ContentJump to Main Navigation
Contents

Financial Disclosure

Chapter:
Manuscript Preparation
Author(s):

Cheryl Iverson

Financial Disclosure

JAMA and the Archives Journals require each author to sign and submit the following financial disclosure statement: “I certify that all my affiliations with or financial involvement within the past 5 years and foreseeable future (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties) with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript are completely disclosed.”1 (See also 5.5, Legal and Ethical Considerations, Conflicts of Interest.)

Authors are expected to provide detailed information about any relevant financial interests or financial conflicts within the past 5 years and for the foreseeable future, particularly those present at the time the research was conducted and up to the time of publication, as well as other financial interests, such as relevant filed or pending patents or patent applications in preparation, that represent potential future financial gain. Although many universities and other institutions and organizations have established policies and thresholds for reporting financial interests and other conflicts of interest, JAMA and the Archives Journals require complete disclosure of all relevant financial relationships and potential financial conflicts of interest, regardless of amount or value. If authors are uncertain about what might constitute a potential financial conflict of interest, they should err on the side of full disclosure and should contact the editorial office if they have questions or concerns. In addition, authors who have no relevant financial interests are asked to provide a statement indicating that they have no financial interests related to the material in the manuscript.

For some journals, financial disclosure information is for the editorial office and is not shared with peer reviewers. Other journals, such as JAMA and the Archives of Dermatology, require authors to include all such disclosures on the title page or in the Acknowledgment section of the manuscript, or both, and these are shown to peer reviewers. However, for all accepted manuscripts, each author’s disclosures of relevant financial interests or declarations of no relevant financial interests should be published. Decisions about whether financial information provided by authors should be published, and thereby disclosed to readers, are usually straightforward. Although editors are willing to discuss disclosure of specific financial information with authors, the policy of JAMA and the Archives Journals is one of full disclosure of all relevant financial interests.

The policy requiring disclosure of financial conflicts of interest should apply for all manuscript submissions, including letters to the editor, opinion pieces, informal essays, and book reviews.

Financial Disclosures: Dr Morrow reported having received research grant support administered via Brigham and Women’s Hospital from Bayer Healthcare Diagnostics, Beckman Coulter, Biosite, Dade Behring, Merck, and Roche Diagnostics; and having received honoraria for educational presentations from Bayer Healthcare Diagnostics, Beckman Coulter, and Dade Behring. Dr de Lemos reported receiving research grants and honoraria and consulting fees for speaking from Biosite and Roche. Dr Blazing reported receiving honoraria from Merck and Pfizer.

Financial Disclosure: Dr Neuzil reported receiving research funding from MedImmune for participation in a multicenter trial of an LAIV in 2004–2005.

Financial Disclosure: Dr Smith reported serving as an expert witness for plaintiffs in US tobacco litigation.

Note: The financial disclosure may be a disclosure of no potential financial conflicts of interest. This is not obligatory, and the choice not to include such a statement should not be misinterpreted as an indication of a conflict. However, the inclusion of a statement like that below removes any ambiguity.

Financial Disclosure: None reported.

Previous | Next